Musculoskeletal Applications of Magnetic Resonance-Guided Focused Ultrasound

2021 ◽  
Vol 25 (06) ◽  
pp. 725-734
Author(s):  
Matthew D. Bucknor ◽  
Joe D. Baal ◽  
Kevin C. McGill ◽  
Andrew Infosino ◽  
Thomas M. Link
Keyword(s):  
Magnetic Resonance ◽  
Bone Metastases ◽  
Focused Ultrasound ◽  
Uterine Fibroids ◽  
The United States ◽  
The Body ◽  
Noninvasive Technique ◽  
Wide Range ◽  
Noninvasive Therapy ◽  
Facet Arthropathy

AbstractMagnetic resonance-guided focused ultrasound (MRgFUS) is a novel noninvasive therapy that uses focused sound energy to thermally ablate focal pathology within the body. In the United States, MRgFUS is approved by the Food and Drug Administration for the treatment of uterine fibroids, palliation of painful bone metastases, and thalamotomy for the treatment of essential tremor. However, it has also demonstrated utility for the treatment of a wide range of additional musculoskeletal (MSK) conditions that currently are treated as off-label indications. Advantages of the technology include the lack of ionizing radiation, the completely noninvasive technique, and the precise targeting that offer unprecedented control of the delivery of the thermal dose, as well as real-time monitoring capability with MR thermometry. In this review, we describe the most common MSK applications of MRgFUS: palliation of bone metastases, treatment of osteoid osteomas, desmoid tumors, facet arthropathy, and other developing indications.

scholarly journals Cost-effectiveness of magnetic resonance guided focused ultrasound for the treatment of uterine fibroids

2009 ◽  
Vol 25 (01) ◽  
pp. 14-25 ◽  
Author(s):  
Amy K. O'Sullivan ◽  
David Thompson ◽  
Paula Chu ◽  
David W. Lee ◽  
Elizabeth A. Stewart ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Magnetic Resonance ◽  
Focused Ultrasound ◽  
Uterine Fibroids ◽  
The United States ◽  
Administrative Database ◽  
Base Case ◽  
Lifetime Horizon ◽  
Secondary Sources ◽  
Life Years

Objectives:The aim of this study is to evaluate the cost-effectiveness of Magnetic Resonance Guided Focused Ultrasound (MRgFUS) compared with alternative treatments for uterine fibroids in the United States.Methods:We used techniques of decision analysis and data from secondary sources to develop and estimate an economic model of the management of uterine fibroids among premenopausal women. Patients in the model receive treatment with MRgFUS, uterine artery embolization (UAE), abdominal myomectomy, hysterectomy, or pharmacotherapy. The model predicts total costs (including subsequent procedures) and quality-adjusted life-years (QALYs) for each treatment strategy over a lifetime horizon, discounted at 3 percent, from a societal perspective. Data on treatment efficacy and safety were obtained from published and unpublished studies. Costs (2005 US$) were obtained from an analysis of a large administrative database and other secondary sources. Lost productivity costs were included in the base-case analysis, but excluded in a sensitivity analysis.Results:UAE was associated with the most QALYs (17.39), followed by MRgFUS (17.36), myomectomy (17.31), hysterectomy (17.18), and pharmacotherapy (16.70). Pharmacotherapy was the least costly strategy ($9,200 per patient), followed by hysterectomy ($19,800), MRgFUS ($27,300), UAE ($28,900), and myomectomy ($35,100). Incremental cost-effectiveness ratios (cost per QALY gained) were $21,800 for hysterectomy, $41,400 for MRgFUS, and $54,200 for UAE; myomectomy was more costly and less effective than both MRgFUS and UAE. Results were sensitive to MRgFUS recurrence rates, MRgFUS procedure costs, and assumptions about quality of life following hysterectomy.Conclusions:Our findings suggest that MRgFUS is in the range of currently accepted criteria for cost-effectiveness, along with hysterectomy and UAE.

Real-Time Magnetic Resonance Guided Focused Ultrasound for Painful Bone Metastases

10.3791/60615 ◽  
2021 ◽  
Author(s):  
Wei-Jun Wang ◽  
Hsin-Lun Lee ◽  
Shiu-Chen Jeng ◽  
Jeng-Fong Chiou ◽  
Yaoru Huang
Keyword(s):  
Magnetic Resonance ◽  
Bone Metastases ◽  
Real Time ◽  
Focused Ultrasound ◽  
Painful Bone Metastases

scholarly journals Updated Costs of Uterine Fibroid Treatments Including Focused Ultrasound Surgery

2018 ◽  
Author(s):  
Bijan J. Borah ◽  
Elizabeth A. Stewart
Keyword(s):  
Magnetic Resonance ◽  
Focused Ultrasound ◽  
Treatment Options ◽  
Uterine Fibroids ◽  
Reproductive Age ◽  
Invasive Treatment ◽  
Ultrasound Surgery ◽  
Non Invasive ◽  
Focused Ultrasound Surgery ◽  
Reproductive Age Women

Uterine leiomyomas (fibroids) affect 20–40% of reproductive age women and are the major indication for hysterectomy. Magnetic Resonance-guided Focused Ultrasound Surgery (MRgFUS) is a new, potentially disruptive, non-invasive and uterine-sparing treatment option that has been shown to yield similar or better clinical outcomes than other uterine-sparing interventions. However, the costs of MRgFUS and other minimally-invasive treatment options have not been studied using US practice data. This study attempts to fill this void. And since uterine fibroids are the first FDA-approved indication for MRgFUS treatment, this study may also have implications for other indications which are now investigational.

scholarly journals Pain Palliation of Bone Metastases Using Magnetic Resonance Guided Focused Ultrasound - Multi-Center Multi-trial Results

2012 ◽  
Vol 23 ◽  
pp. ix463 ◽  
Author(s):  
R. Catane ◽  
D. Gianfelice ◽  
M. Kawasaki ◽  
D. Iozeffi ◽  
S. Kanyev ◽  
...  
Keyword(s):  
Magnetic Resonance ◽  
Bone Metastases ◽  
Focused Ultrasound ◽  
Pain Palliation
Sign in / Sign up

Export Citation Format

Share Document